These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 32279709)

  • 1. Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease.
    Poewe W; Mahlknecht P
    Neurol Clin; 2020 May; 38(2):255-267. PubMed ID: 32279709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and experimental treatments of Parkinson disease: A guide for neuroscientists.
    Oertel W; Schulz JB
    J Neurochem; 2016 Oct; 139 Suppl 1():325-337. PubMed ID: 27577098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the pharmacologic management of early Parkinson disease.
    Hauser RA; Zesiewicz TA
    Neurologist; 2007 May; 13(3):126-32. PubMed ID: 17495756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternatives to levodopa in the initial treatment of early Parkinson's disease.
    Lees A
    Drugs Aging; 2005; 22(9):731-40. PubMed ID: 16156677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apomorphine and levodopa infusion for motor fluctuations and dyskinesia in advanced Parkinson disease.
    Antonini A; Nitu B
    J Neural Transm (Vienna); 2018 Aug; 125(8):1131-1135. PubMed ID: 30006821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of levodopa-induced motor complications.
    Stocchi F; Tagliati M; Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S599-612. PubMed ID: 18781681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
    Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
    J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment of Parkinson disease: a review.
    Connolly BS; Lang AE
    JAMA; 2014 Apr 23-30; 311(16):1670-83. PubMed ID: 24756517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.
    Seppi K; Weintraub D; Coelho M; Perez-Lloret S; Fox SH; Katzenschlager R; Hametner EM; Poewe W; Rascol O; Goetz CG; Sampaio C
    Mov Disord; 2011 Oct; 26 Suppl 3(0 3):S42-80. PubMed ID: 22021174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Off spells and dyskinesias: pharmacologic management of motor complications.
    Khan TS
    Cleve Clin J Med; 2012 Jul; 79 Suppl 2():S8-13. PubMed ID: 22761271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.
    Fox SH; Katzenschlager R; Lim SY; Barton B; de Bie RMA; Seppi K; Coelho M; Sampaio C;
    Mov Disord; 2018 Aug; 33(8):1248-1266. PubMed ID: 29570866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
    Deleu D; Northway MG; Hanssens Y
    Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004.
    Goetz CG; Poewe W; Rascol O; Sampaio C
    Mov Disord; 2005 May; 20(5):523-39. PubMed ID: 15818599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Duodenale levodopa and apomorphine infusion for motor complications in advanced Parkinson's disease].
    Antonini A; Jost WH
    Fortschr Neurol Psychiatr; 2018 Sep; 86(S 01):S5-S9. PubMed ID: 30107620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
    Tse W
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current management of motor fluctuations in patients with advanced Parkinson's disease treated chronically with levodopa.
    Melamed E; Zoldan J; Galili-Mosberg R; Ziv I; Djaldetti R
    J Neural Transm Suppl; 1999; 56():173-83. PubMed ID: 10370911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.